文献速递胸部肿瘤

纵向不可检测的分子残留病灶定义局部非小细胞肺癌潜在治愈人群

Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.
PubMed 文献 · Cancer Discov · 2022-01-01

该研究纳入261例接受根治性手术的I至III期非小细胞肺癌患者,成功检测913份外周血样本的分子残留病灶(MRD)。纵向不可检测MRD患者仅6例(3.2%)复发,阴性预测值为96.8%;纵向可检测MRD阳性预测值为89.1%,中位领先时间3.4个月。

要点

  • 纵向不可检测MRD的局部NSCLC患者复发率低,阴性预测值96.8%。
  • 纵向可检测MRD阳性预测值89.1%,中位领先时间3.4个月。
  • 仅脑部复发较少被MRD检出(n=1/5,20%)。

核心结论

  • 纵向不可检测MRD可能定义局部非小细胞肺癌的潜在治愈人群,与分期和辅助治疗无关。
  • 纵向可检测MRD的阳性预测值为89.1%,中位领先时间3.4个月。
  • 脑部仅复发较少被MRD检出(n=1/5,20%)。

研究设计与样本

  • 研究纳入261例接受根治性手术的I至III期非小细胞肺癌患者,成功检测913份外周血样本的MRD。

主要发现

  • 纵向不可检测MRD患者中仅6例(3.2%)复发,阴性预测值为96.8%。
  • 纵向可检测MRD的阳性预测值为89.1%,中位领先时间为3.4个月。
  • 脑部仅复发较少被MRD检出(n=1/5,20%)。
  • 亚组分析显示不可检测MRD的患者可能无法从辅助治疗中获益。
  • 可检测MRD的风险在标志性检测后约18个月达峰,此后逐步下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The efficacy and potential limitations of molecular residual disease (MRD) detection urgently need to be fully elucidated in a larger population of non-small cell lung cancer (NSCLC). We enrolled 261 patients with stages I to III NSCLC who underwent definitive surgery, and 913 peripheral blood samples were successfully detected by MRD assay. Within the population, only six patients (3.2%) with longitudinal undetectable MRD recurred, resulting in a negative predictive value of 96.8%. Longitudinal undetectable MRD may define the patients who were cured. The peak risk of developing detectable MRD was approximately 18 months after landmark detection. Correspondingly, the positive predictive value of longitudinal detectable MRD was 89.1%, with a median lead time of 3.4 months. However, brain-only recurrence was less commonly detected by MRD (n = 1/5, 20%). Further subgroup analyses revealed that patients with undetectable MRD might not benefit from adjuvant therapy. Together, these results expound the value of MRD in NSCLC. SIGNIFICANCE: This study confirms the prognostic value of MRD detection in patients with NSCLC after definitive surgery, especially in those with longitudinal undetectable MRD, which might represent the potentially cured population regardless of stage and adjuvant therapy. Moreover, the risk of developing detectable MRD decreased stepwise after 18 months since landmark detection. This article is highlighted in the In This Issue feature, p. 1599.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhang JT, Liu SY, Gao W, et al. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer. Cancer Discov. 2022. PMID: 35543554. doi:10.1158/2159-8290.CD-21-1486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。